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of theirAbstract A novel series of 3-(4, 5-dihydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-
chromen-2-one derivatives were synthesized. In the ﬁrst step salicylaldehyde was reacted with ethy-
lacetoacetate at room temperature by stirring which gives compound (I). Compound (I) when
reﬂuxed with substituted benzaldehyde and diethylamine in the presence of n-butanol for 4–5 h
gives substituted derivatives (IIa–d). Compounds synthesized in step 2 when reﬂuxed with phenyl
hydrazine in the presence of pyridine for 6–7 h gives the title compounds (IIIa–d). All the synthe-
sized compounds were sent to NCI for anticancer activity. Synthesized compounds were tested for
anticancer activity against 60 different cell lines. From the data thus obtained it was observed that
simple coumarin ring derivatives were more effective in inhibiting the growth of cancerous cell lines,
than coumarin-pyrazoline derivatives. Among all the synthesized compounds, irrespective of com-
pounds having simple coumarin ring and coumarin-pyrazoline combination, compounds IIa–c, IIIb
and IIId were potent anticancer agents. Compounds were active for the single dose therapeutic pro-
gram at the dose of 1.00E-5 molar concentration. The main anti cancer activity is assumed to be due
to the presence of the lactone structure in coumarin moiety.
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anticancer activity. Arabian Journ1. Introduction
Cancer is the uncontrolled growth of cells coupled with malig-
nant behavior: invasion and metastasis. Cancer is thought to
be caused by the interaction between genetic susceptibility and
environmental toxins. Anticancer drugs available are targeted
to damage the aberrantly dividing cell by interrupting the cell
division process (Carter et al., 1986). Some of anti cancer agents
used include DNA intercalating agents (e.g. adriamycin), DNA
cross-linking agents (e.g. cisplatin), topoisomerase inhibitors
(e.g. campothecins), cytoskeleton-disrupting agents (e.g.ing Saud University.
hydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Scheme 1 Synthesis of 3-(4, 5-dihydro-1-phenyl-5-substituted
phenyl-1H-pyrazol-3-yl)-2Hchromen-2-one derivatives. Reagents
and conditions: (i) Diethylamine, stir, RT, 20 min; (ii) Substituted
benzaldehydes, diethylamine/n-butanol, reﬂux, 4 h; (iii) Phenyl
hydrazine, Pyridine, reﬂux, 6 h.
2 N. Kumar et al.vinblastin) and antimetabolites (e.g. mercaptopurine). These
drugs affect ‘‘younger’’ tumors (i.e., more differentiated) more
effectively, because they still possess some regulated cell growth.
With succeeding generations of tumor cells, differentiation is
typically lost, growth becomes less regulated, and tumors be-
come less responsive to most chemotherapeutic agents. Near
the center of some solid tumors, cell division has effectively
ceased, making them insensitive to chemotherapy.
These anticancer agents though effective, are cytotoxic, and
thus exhibit severe side effects, particularly on normal prolifer-
ating tissues such as the hematopoietic system (Baroniya et al.,
2010). Many natural products and other chemicals are put in
to reduce the overall side effects of these chemotherapeutic
agents. Recently coumarins and its derivatives are extensively
studied to treat various types of cancer. Coumarins can be
used not only to treat cancer but also to treat the side effects
caused by radiotherapy. A recent study investigated the efﬁ-
cacy of coumarin/troxerutine combination therapy for the pro-
tection of salivary glands and mucosa in patients undergoing
head and neck radiotherapy. The results suggest that couma-
rin/troxerutine have a favorable effect in the treatment of
radiogenic sialadentis and mucositis (Grotz et al., 2001). Cou-
marin and coumarin-related compounds have proved for many
years to have signiﬁcant therapeutic potential. They come from
a wide variety of natural sources and new coumarin derivatives
are being discovered or synthesized on a regular basis. Couma-
rin is a simple molecule and many of its derivatives have been
known for more than a century. However, their vital role in
plant and animal biology has not been fully exploited. Couma-
rins have multiple biological activities including disease pre-
vention, growth modulation and anti oxidant properties.
These derivatives have anti-tumor effects and can cause signif-
icant changes in the regulation of immune responses, cell
growth and differentiation.
In the ﬁeld of chemotherapy some newer agents are intro-
duced which do not directly interfere with DNA. These include
monoclonal antibodies and the new tyrosine kinase inhibitors
e.g. imatinib mesylate (Gleevec or Glivec), which directly tar-
gets a molecular abnormality in certain types of cancer
(chronic myelogenous leukemia and gastrointestinal stromal
tumors). These are examples of targeted therapies. In addition,
some drugs that modulate tumor cell behavior without directly
attacking those cells may be used. Hormone treatments fall
into this category. In case of coumarins as anti cancer agents
they act by different mechanisms for different cancerous cell
lines (Lacy and O’Kennedy, 2004).2. Materials and methods
Reaction Scheme: (See Scheme 1).
2.1. Synthesis
2.1.1. General procedure for synthesis of 3-acetyl coumarin (I)
To the cold ethylacetoacetate solution (5 ml, 0.2 M) salicyal-
dehyde (5 ml, 0.2 M) was added dropwise, few drops of cat-
alyst (diethylamine) were added by continuous and rapid
stirring. After 20 min the yellow solid separated was ﬁltered
off subsequently washed with ethanol and was recrystallized
by ethanol.Please cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journ2.1.2. General procedure for synthesis of 3-substituted phenyl-1-
(3-coumarinyl) propan-1-ones (IIa–d)
A mixture of 3-acetyl coumarin (A, 0.01 M) and different
substituted benzaldehydes (0.012 M) were dissolved in 10 ml
of n-butanol under heating; (Singh et al., 2011) then 0.3 ml
of glacial acetic acid and the same quantity of catalyst (dieth-
ylamine) were added. The reaction mixture was reﬂuxed for 4 h
and then solvent was removed. The residue was washed with
ethanol to remove the remaining solvent. The precipitate was
ﬁltered off and crystallized from appropriate solvent.
2.1.3. General procedure for synthesis of 3-(4, 5-dihydro-1-
phenyl-5-substituted phenyl-1Hpyrazol- 3-yl)-2H-chromen-2-
one (IIIa–d)
3-substituted phenyl-1-(3-coumarinyl) propan-1-ones (B,
0.05 M) were dissolved in pyridine (30 ml), with slight heating
then hydrazine hydrate (0.2 M) was added to the mixture
which was reﬂuxed for 6 h. On completion of reaction, neutral-
ization was done with 2 N hydrochloric acid. Neutralized reac-
tion mixture was poured onto the crushed ice. The precipitated
solid was ﬁltered, dried and recrystallized from appropriate
solvent to yield the desired compound (IIIa–d). The com-
pounds were characterized by their physiochemical parame-
ters, IR, 1H-NMR, Mass and elemental analysis data.
All the research chemicals were purchased from sigma–Al-
drich (St. Louis, Missouri, USA) and are used as such for the
reactions. Reactions were monitored by thin-layer chromatog-
raphy (TLC) using silica gel by ascending technique. Melting
points of the synthesized compounds were determined by open
capillary method and were uncorrected. IR spectra were re-
corded on Shimadzu FTIR-84005 by using KBr pellet tech-
nique. The 1H NMR was recorded on Brucker DRX-300
(300 MHz FT NMR with low and high temperature facility)
usingCDCl3/DMSO-d6 as solvent. Chemical shifts are reported
in dppmunits with respect toTMSas internal standard. The ele-
mental analysis (C, H, and O) of compounds was performed on
Elementar Vario EL III, carlo Erba 1108 analyzer. Results of
elemental analysis were within±0.5% of the theoretical values.
Purity of the compounds was checked onTLCplates using silica
gel G as stationary phase and iodine vapors as visualizing
agents.hydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Synthesis of coumarin derivatives and their anticancer activity 32.2. Methodology of the in vitro cancer screen
The human tumor cell lines of the cancer screening panel are
grown in RPMI 1640 medium containing 5% fetal bovine ser-
um and 2 mM L-glutamine. For a typical screening experiment,
cells are inoculated into 96 well microtiter plates in 100 lL at
plating densities ranging from 5,000 to 40,000 cells/well
depending on the doubling time of individual cell lines. After
cell inoculation, the microtiter plates are incubated at 37 C,
5% CO2, 95% air and 100% relative humidity for 24 h prior
to the addition of experimental drugs (Chaudhary et al., 2011).
After 24 h, two plates of each cell line are ﬁxed in situ with
TCA, to represent a measurement of the cell population for
each cell line at the time of drug addition (Tz). Experimental
drugs are solubilized in dimethyl sulfoxide at 400-fold the de-
sired ﬁnal maximum test concentration and stored frozen prior
to use. At the time of drug addition, an aliquot of frozen con-
centrate is thawed and diluted to twice the desired ﬁnal maxi-
mum test concentration with complete medium containing
50 lg/ml gentamicin. Additional four, 10-fold or ½ log serial
dilutions are made to provide a total of ﬁve drug concentra-
tions plus control. Aliquots of 100 ll of these different drug
dilutions are added to the appropriate microtiter wells already
containing 100 ll of medium, resulting in the required ﬁnal
drug concentrations (Dudhe et al., 2012).
Following drug addition, the plates are incubated for an
additional 48 h at 37 C, 5% CO2, 95% air, and 100% relative
humidity. For adherent cells, the assay is terminated by the
addition of cold TCA. Cells are ﬁxed in situ by the gentle addi-
tion of 50 ll of cold 50% (w/v) TCA (ﬁnal concentration, 10%
TCA) and incubated for 60 min at 4 C. The supernatant is
discarded, and the plates are washed ﬁve times with tap water
and air dried. Sulforhodamine B (SRB) solution (100 ll) at
0.4% (w/v) in 1% acetic acid is added to each well, and plates
are incubated for 10 min at room temperature. After staining,
unbound dye is removed by washing ﬁve times with 1% acetic
acid and the plates are air dried. Bound stain is subsequently
solubilized with 10 mM trizma base, and the absorbance is
read on an automated plate reader at a wavelength of
515 nm. For suspension cells, the methodology is the same ex-
cept that the assay is terminated by ﬁxing settled cells at the
bottom of the wells by gently adding 50 ll of 80% TCA (ﬁnal
concentration, 16% TCA). Using the seven absorbance mea-
surements [time zero (Tz), control growth (C), and test growth
in the presence of drug at the ﬁve concentration levels (Ti)], the
percentage growth is calculated at each of the drug concentra-
tions levels. Percentage growth inhibition is calculated as:
½ðTi TzÞ=ðC TzÞ  100 for concentrations for which Ti
> = ¼ Tz
½ðTi TzÞ=Tz  100 for concentrations for which Ti < Tz:
Three dose response parameters are calculated for each exper-
imental agent. Growth inhibition of 50% (GI50) is calculated
from [(Ti  Tz)/(C  Tz)] · 100 = 50, which is the drug con-
centration resulting in a 50% reduction in the net protein in-
crease (as measured by SRB staining) in control cells during
the drug incubation. The drug concentration resulting in total
growth inhibition (TGI) is calculated from Ti = Tz. The LC50
(concentration of drug resulting in a 50% reduction in the
measured protein at the end of the drug treatment as comparedPlease cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journto that at the beginning) indicating a net loss of cells following
treatment is calculated from [(Ti  Tz)/Tz] · 100 = 50. Val-
ues are calculated for each of these three parameters if the level
of activity is reached; however, if the effect is not reached or is
exceeded, the value for that parameter is expressed as greater
or less than the maximum or minimum concentration tested
(www.dtp.nci.nih.gov).
3. Result
All the synthesized compounds were characterized by IR, 1H
NMR, Mass spectroscopy and elemental analysis, with their
following spectral data:
3.1. 3-Acetyl coumarin (I)
IR (KBr)Vmax: 1741.60(Lactone of coumarin), 1677.95(C‚O),
1454.23(Ar C‚C), 757.97(Ar‚C-Hdef); 1H NMR (CDCl3-d6
300 MHz, d ppm): d 7.38–7.47 (m, 4H, Ar–H), 8.65 (s, 1H, H
of coumarin), 2.5 (s, 3H, –CH3); EIMS m/z: 189, 171, 135;
Anal. Cal. C, 70.21; Found, C, 70.80%.
3.2. 3-(3-(2, 4-Dichlorophenyl) acryloyl)-2H-chromen-2-one
(IIa)
IR (KBr)Vmax: 1741.60 (Lactone of coumarin),
1677.95(C‚O), 1454.23(Ar C‚C), 757.97(Ar‚C-Hdef),
1080.06 (Ar C–Cl); 1H NMR (CDCl3-d6 300 MHz, d ppm):
d 7.22–7.38 (m, 8H, Ar–H), 8.40 (s, 1H, H of coumarin),
4.15 (dd, 1H, H cis of ethylene), 3.18 (dd, 1H, H trans of eth-
ylene); Anal. Cal. C, 62.63; Found, C, 63.12%.
3.3. 3-(3-(2, 6-Dichlorophenyl) acryloyl)-2H-chromen-2-one
(IIb)
IR (KBr)Vmax:1731.96 (Lactone of coumarin), 1527.52 (Ar–
C‚C), 1660.60 (–C‚O), 1608.52 (–C‚Cstr), 979.77 (Ar C–
Cl) ; 1H NMR (CDCl3-d6 300 MHz, d ppm):d 7.02–7.27 (m,
8H, Ar–H), 8.45 (s, 1H, H of coumarin), 4.15 (dd, 1H, H cis
of ethylene), 3.54 (dd, 1H, H trans of ethylene); Anal. Cal.
C, 62.63; Found, C, 61.23%.
3.4. 3-(3-(2, 4-Dimethoxyphenyl) acryloyl)-2H-chromen-2-one
(IIc)
IR (KBr)Vmax: 1722.31 (Lactone of coumarin), 1556.45 (Ar
C‚C) , 1606.59 (–C‚Cstr),1384.79 (Ar–C–OCH3), 1172.64
(–OCH3); 1H NMR (CDCl3-d6 300 MHz, d ppm): d 7.02–
7.27 (m, 8H, Ar–H), 8.49 (s, 1H, H of coumarin), 4.25 (dd,
1H, H cis of ethylene), 3.50 (dd, 1H, H trans of ethylene),
3.37 (s, 6H, –OCH3); Anal. Cal. C, 71.42; Found, C, 71.50%.
3.5. 3-(3-(4-Hydroxyphenyl) acryloyl)-2H-chromen-2-one (IId)
IR (KBr)Vmax: 1726.95 (Lactone of coumarin), 1550.24 (Ar
C‚C), 1589.34 (–C‚Cstr) ; 1H NMR (CDCl3-d6 300 MHz,
d ppm): d 7.02–7.27 (m, 8H, Ar–H), 8.42 (s, 1H, H of couma-
rin), 4.24 (dd, 1H, H cis of ethylene), 3.50 (dd, 1H, H trans of
ethylene), 3.37 (s, 6H, –OCH3), 3.12 (s, 1H, –OH); Anal. Cal.
C, 71.42; Found, C, 71.50%.hydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Table 1 60 Cell line assay of compound IIa in one dose at 105 concentration.
60 Cell line assay in one dose at 105 concentration
Mean growth percentage Range of growth percentage Most sensitive cell line Growth of most sensitive cell line percentage
IIa 102.37 25.60 to 60.55 UO-31 25.60
IIa 102.37 19.55 to 60.55 SK-ME 4–5 19.55
IIa 102.37 15.50 to 60.55 SNB-75 15.50
IIa 102.37 14.8 to 60.55 MDA-MB-231 14.80
UO-31: Renal cancer lines; SK-ME 4–5: Melanoma cell lines; SNB-75: CNS cancer cell lines; MDA-MB-231: Breast cancer cell lines.
Table 2 60 Cell line assay of compound IIb in one dose at 105 concentration.
60 Cell line assay in one dose at 105 concentration
Mean growth percentage Range of growth percentage Most sensitive cell line Growth of most sensitive cell line percentage
IIb 91.78 42.88 to 73.75 UO-31 42.88
IIb 91.78 35.15 to 73.75 MDA-MB-231 35.15
IIb 91.78 33.68 to 73.75 HOP-62 33.68
UO-31: Renal cancer cell lines; MDA-MB-231: Breast cancer cell lines; HOP-62: Non-small cell lung cancer cell lines.
Table 3 60 Cell line assay of compound IIc in one dose at 105 concentration.
60 Cell line assay in one dose at 105 concentration
Mean growth percentage Range of growth percentage Most sensitive cell line Growth of most sensitive cell line percentage
IIc 91.85 52.42 to 73.84 MDA-MB-468 52.42
IIc 91.85 46.70 to 73.84 NCI-H522 46.70
IIc 91.85 40.04 to 73.84 CAKI-1 40.04
IIc 91.85 31.53 to 73.84 T-47D 31.53
MDA-MB-468: Breast cancer cell lines; NCI-H522: Non-small cell lung cancer cell lines; CAKI-1: Renal cancer cell lines; T-47D: Breast cancer
cell lines.
Table 4 60 Cell line assay of compound IIIb in one dose at 105 concentration.
60 Cell line assay in one dose at 105 concentration
Mean growth percentage Range of growth percentage Most sensitive cell line Growth of most sensitive cell line percentage
IIIb 98.35 24.33 to 55.07 NCI-H23 24.33
IIIb 98.35 28.42 to 55.07 CAKI-1 28.42
IIIb 98.35 29.18 to 55.07 MDA-MB-231/ATCC 29.18
NCI-H23: Non-small cell lung cancer cell lines; CAKI-1: Renal cancer cell lines; MDA-MB-231/ATCC: Breast cancer cell lines.
Table 5 60 Cell line assay of compound IIId in one dose at 105 concentration.
60 cell line assay in one dose at 105 concentration
Mean growth percentage Range of growth percentage Most sensitive cell line Growth of most sensitive cell line percentage
IIId 77.59 67.37 to 78.46 MDA-MB-231/ATCC 67.37
IIId 77.59 65.18 to 78.46 CAKI-1 65.18
IIId 77.59 63.77 to 78.46 UO-31 63.77
IIId 77.59 67.37 to 78.46 NCI-H522 67.37
MDA-MB-231/ATCC: Breast cancer cell lines; CAKI-1: Renal cancer cell lines; UO-31: Renal cancer cell lines; NCI-H522: Non-small cell lung
cancer.
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Figure 1 Anti cancer spectra of compound IIa.
Synthesis of coumarin derivatives and their anticancer activity 53.6. 3-(4, 5-Dihydro-5-(2, 4-dichlorophenyl)-1-phenyl-1H-
pyrazol-3-yl)-2H-chromen-2-one (IIIa)
IR (KBr)Vmax: 1693.38 (Lactone of coumarin), 1498.59 (Ar
C‚C), 1548.73 (–C‚Cstr), 1598.88 (–C‚N) , 1072.35 (Ar C–
Cl); 1H NMR (CDCl3-d6 300MHz, d ppm): 6.43–7.27 (m, 12H,
Ar–H), 7.4 (s, 1H, H of coumarin), 4.82 (d, 1H, 5-H of pyrazoline),
3.39 (d, 1H, 4-Htrans of pyrazoline), 4.33 (d, 1H, 4-Hcis of pyraz-
oline); Anal. Cal. C, 66.22, N, 6.44; Found, C, 66.24, N, 6.42%.Please cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journ3.7. 3-(4, 5-Dihydro-5-(2, 6-dichlorophenyl)-1-phenyl-1H-
pyrazol-3-yl)-2H-chromen-2-one (IIIb)
IR (KBr)Vmax: 1731.96 (Lactone of coumarin), 1527.52 (Ar
C‚C), 1660.60 (–C‚Cstr), 1588.50 (–C‚N), 979.77 (Ar C–Cl);
1H NMR (CDCl3-d6 300MHz, d ppm): d 6.43–7.27 (m, 12H,
Ar–H), 7.4 (s, 1H, H of coumarin), 4.98 (d, 1H, 5-H of pyrazoline),
3.79(d, 1H, 4-Htrans of pyrazoline), 3.84 (d, 1H, 4-Hcis of pyraz-
oline); Anal. Cal. C, 66.22, N, 6.44; Found, C, 65.58, N, 6.15%.hydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Figure 2 Anti cancer spectra of compound IIb.
6 N. Kumar et al.3.8. 3-(4, 5-Dihydro-5-(2, 4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-2H-chromen-2-one (IIIc)
IR (KBr)Vmax: 1721.54 (Lactone of coumarin), 1556.45 (Ar
C‚C), 1606.59 (–C‚Cstr), 1596.95 (–C‚N) , 1172.64 (–
OCH3); 1H NMR (CDCl3-d6 300 MHz, d ppm): 6.23–7.27
(m, 12H, Ar–H), 7.42 (s, 1H, H of coumarin), 3.73 (s, 6H of
–OCH3), 4.88 (d, 1H, 5-H of pyrazoline), 3.29(d, 1H, 4-HtransPlease cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journof pyrazoline), 3.33 (d, 1H, 4-Hcis of pyrazoline); Anal. Cal. C,
73.23, N, 6.57; Found, C, 73.54, N, 6.42%.
3.9. 3-(4, 5-Dihydro-5-(4-hydroxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-2H-chromen-2-one (IIId)
IR (KBr)Vmax: 1726.44 (Lactone of coumarin), 1550.15 (Ar
C‚C), 1624.43 (–C‚Cstr), 1590.95 (–C‚N); 1H NMRhydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Figure 3 Anti cancer spectra of compound IIc.
Synthesis of coumarin derivatives and their anticancer activity 7(CDCl3-d6 300 MHz, d ppm): 6.23–7.27 (m, 12H, Ar–H), 7.42
(s, 1H, H of coumarin), 3.03 (s, 1H of –OH), 4.88 (d, 1H, 5-H
of pyrazoline), 3.69(d, 1H, 4-Htrans of pyrazoline), 3.83 (d,
1H, 4-Hcis of pyrazoline); Anal. Cal. C, 71.24, N, 6.57; Found,
C, 70.62, N, 6.42%.
After synthesis and their characterization compounds were
submitted to the NCI 60 cell line screen, which were evaluated
initially at a single concentration (10–5 M) in the full NCI 60Please cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journcell panel. 60 different human tumor cell lines, representing
leukemia, non-small cell lung cancer, colon cancer, CNS can-
cer, melanoma, ovarian cancer, renal cancer, prostate cancer,
and breast cancer were utilized in the screening. (See Tables
1–4).
The mean growth, range of growth, and growth relative to
most sensitive cell lines are depicted to evaluate the efﬁcacy of
the compounds. A broad spectrum of growth inhibitoryhydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Figure 4 Anti cancer spectra of compound IIIb.
8 N. Kumar et al.activity against human tumor cell, as well as some distinctive
patterns of selectivity has been shown by the tested com-
pounds. Compound IIId of Table 5 was found to be a most ac-
tive anticancer agent among all other synthesized compounds
with minimum mean growth percentage of 77.59.
Maximum inhibition was observed for the cancer cell lines
of Renal cancer, Breast cancer and Non-small cell lung cancer.
Most inhibited cell lines were Breast cancer (MDA-MB-231/Please cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian JournATCC) and Non-small cell lung cancer (NCI-H522) with
growth percentage of 67.37 each as shown in Fig. 5. Other
next potent compounds were IIa–c, IIIb with growth percent-
age of 102.37, 91.78, 91.85 and 98.35 as shown in Figs. 1–4
respectively. (See Graph. 1).
From the results obtained it is evident that the compounds
are more effective on Breast cancer cell lines. While comparing
the chemical structures of these compounds it shows thathydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Figure 5 Anti cancer spectra of compound IIId.
Synthesis of coumarin derivatives and their anticancer activity 9simple coumarin derivatives (step II) are more effective in
inhibiting the growth of cell lines than compared to the couma-
rin-pyrazoline derivatives.
4. Discussion
Coumarins can be used not only to treat cancer but also to
treat the side effects caused by radiotherapy. Here thePlease cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journcoumarin derivatives proved to be very effective for speciﬁc
cancer cell lines. These derivatives are effective for the renal,
breast and non-small cell lung cancers.
Coumarins and their derivatives mainly act upon the cell
growth cycle of the cancerous cells due to their lactone ring
present in them. In every cancerous cell lines they have differ-
ent actions on the different stages of cell cycle. It has been
investigated that coumarins induce G1 arrest of human renalhydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-
al of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.008
Graph 1 Growth percentage on different cell lines.
10 N. Kumar et al.cancer cell lines, from the results it is evident that hydroxy sub-
stitution on coumarin-pyrazoline moiety is proved to be most
effective as cytotoxic agents.
The d-lactone ring of the coumarins is tried to be co-related
with the d-lactone rings of well established Camptothecin es-
ters and sesiquiterpene lactones. Literature shows that these
compounds act as anticancer agents by resisting hydrolysis
while in circulation, but hydrolyzing their intact lactone ring
in the target tissue. Rates of hydrolysis by tumor cells may
vary and it is the chief feature which determines the potency
of the compounds for particular cancerous cell.
Camptothecins contain a lactone ring that exists in the
closed form below pH 7. Above 7, the open (CPT+) and the
closed (CPT) form coexist in a 90–10 ratio in human plasma
due to the high afﬁnity of human serum albumin (HSA) for
CPT+. CPT+ is much less toxic than CPT and it is excreted
much faster. Due to variation of rates of hydrolysis Camptot-
hecins were higher by breast cancer and melanoma cells than
by colon cancer cells. Apart from hydrolysis, other proposed
mechanisms could be that of sesiquiterpene-lactones. SLs react
with thiols, such as cysteine residues in the protein, by rapid
Michael type of addition. These reactions are mediated chem-
ically by a,b-unsaturated carbonyl system present in the SLs.
These studies support the view that SLs inhibit tumor growth
by selective alkylation of growth regulatory biological macro-
molecules such as key enzymes, which controls cell division,
thereby inhibiting a variety of cellular functions, which directs
the cell into apoptosis. However, other factors, such as
lipophilicity, molecular geometry, and chemical environmentPlease cite this article in press as: Kumar, N. et al., Synthesis of 3-(4, 5-di
one derivatives and evaluation of their anticancer activity. Arabian Journor the target sulfhydryl may also inﬂuence the activity of
lactones.
Like these lactone moieties, d-lactone ring of the coumarins
possesses their anti-cancer activity. With various substitutions
the hydrolysis of the lactone in the circulation could be pre-
vented and thus this lactone ring by get hydrolyzed by the tu-
mor cells which further may arrest cell division. Here in the
present article compound IIId (4-hydroxy substitution) was
the most potent anti cancer agent speciﬁcally for the Breast
cancer (MDA-MB-231/ATCC) and Non-small cell lung cancer
(NCI-H522).Acknowledgement
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